newsfilter
← Latest News
GlobeNewswire·

Genelux Corporation Reports Third Quarter 2025 Financial Results and Provides General Business Updates

-- Lung cancer programs progressing with interim data updates expected in Q4 2025 -- -- Topline data from OnPrime Phase 3 ovarian cancer registrational trial expected in the second half of 2026 -- -- Cash, cash